All enrolled clients who gained at least one dose of zosuquidar or placebo all through induction were being monitored with the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse situations were being relevant to the period of extended and important myelosuppression https://25-hydroxycholesterol00986.59bloggers.com/28480251/helping-the-others-realize-the-advantages-of-imdk